A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
France- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to France642 clinical trials in Rouen, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FranceEssaisCliniques.fr(opens in a new tab)
France
France
France
France
France
France
France
France
France
France
France
FranceThe busiest research cities in the country
What the registry says about research in the country
Clinical trials focusing on innovative treatments for various cancers, including head and neck squamous cell carcinoma, bladder cancer, and breast cancer. Studies are evaluating novel therapeutic combinations and targeted approaches.
Multiple studies are investigating new drug combinations and personalized treatment approaches.
Research initiatives examining treatments for Alzheimer's disease, frontotemporal dementia, and multiple sclerosis. Studies focus on understanding disease mechanisms and testing novel therapeutic approaches.
Innovative approaches using advanced imaging and biomarker analysis are being explored.
Studies investigating treatments for heart failure prevention and pulmonary hypertension. Research includes evaluation of new therapeutic agents and combination treatments.
Focus on developing safer and more effective cardiovascular treatments.
Tell us about your condition – we search every trial in Europe and connect you with the right site.